Fenbufen

Identification

Generic Name
Fenbufen
DrugBank Accession Number
DB08981
Background

Fenbufen is a non-steroidal anti-inflammatory drug used primarily to treat inflammation in osteoarthritis, ankylosing spondylitis, and tendinitis. It can also be used to relieve backaches, sprains, and fractures. Fenbufen is available as a capsule or tablet sold with the brand names Cepal, Cinopal, Cybufen, Lederfen, and Reugast. Fenbufen acts by preventing cyclooxygenase from producing prostaglandins which can cause inflammation.

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 254.2806
Monoisotopic: 254.094294314
Chemical Formula
C16H14O3
Synonyms
  • 3-(4-Biphenylylcarbonyl)propionic acid
  • 3-(4-Phenylbenzoyl)propionic acid
  • 4-(4-Biphenylyl)-4-oxobutyric acid
  • Fenbufen
  • Fenbufén
  • Fenbufène
  • Fenbufenum
  • gamma-oxo(1,1'-biphenyl)-4-butanoic acid
External IDs
  • CL 82,204
  • CL-82204

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofAcute gouty arthritis•••••••••••••••••••
Treatment ofOsteoarthritis (oa)•••••••••••••••••••
Treatment ofPost operative pain•••••••••••••••••••
Treatment ofPostoperative dental pain•••••••••••••••••••
Treatment ofRheumatoid arthritis•••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirFenbufen may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Abciximab.
AcebutololFenbufen may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Fenbufen.
AcemetacinThe risk or severity of adverse effects can be increased when Fenbufen is combined with Acemetacin.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
M01AE05 — Fenbufen
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Alkyl-phenylketones
Alternative Parents
Biphenyls and derivatives / Butyrophenones / Gamma-keto acids and derivatives / Benzoyl derivatives / Aryl alkyl ketones / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives
Substituents
Alkyl-phenylketone / Aromatic homomonocyclic compound / Aryl alkyl ketone / Benzenoid / Benzoyl / Biphenyl / Butyrophenone / Carboxylic acid / Carboxylic acid derivative / Gamma-keto acid
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
biphenyls, 4-oxo monocarboxylic acid (CHEBI:31599)
Affected organisms
Not Available

Chemical Identifiers

UNII
9815R1WR9B
CAS number
36330-85-5
InChI Key
ZPAKPRAICRBAOD-UHFFFAOYSA-N
InChI
InChI=1S/C16H14O3/c17-15(10-11-16(18)19)14-8-6-13(7-9-14)12-4-2-1-3-5-12/h1-9H,10-11H2,(H,18,19)
IUPAC Name
4-{[1,1'-biphenyl]-4-yl}-4-oxobutanoic acid
SMILES
OC(=O)CCC(=O)C1=CC=C(C=C1)C1=CC=CC=C1

References

Synthesis Reference

U.S. Patent 3,784,701.

General References
Not Available
KEGG Drug
D01344
PubChem Compound
3335
PubChem Substance
310264942
ChemSpider
3218
BindingDB
50240374
RxNav
24830
ChEBI
31599
ChEMBL
CHEMBL277522
ZINC
ZINC000000001427
PharmGKB
PA166049176
Wikipedia
Fenbufen

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Capsule
Capsule300 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)185-187U.S. Patent 3,784,701.
Predicted Properties
PropertyValueSource
Water Solubility0.0121 mg/mLALOGPS
logP3.07ALOGPS
logP3Chemaxon
logS-4.3ALOGPS
pKa (Strongest Acidic)4.22Chemaxon
pKa (Strongest Basic)-7.5Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area54.37 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity72.49 m3·mol-1Chemaxon
Polarizability27.47 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSsplash10-05nu-5910000000-f91ec96f1a16f6d0bbba
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0f89-2900000000-b30afcea40626e90c194
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4r-0090000000-482ad8ce3536a4b63b93
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0670-0090000000-842ecd4363ae336f1b26
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-0980000000-5eba221df6673102bd3a
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0pb9-3980000000-bdfa5cf45c8265c1fb6b
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a5c-0910000000-1ee1def8251005d648c7
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0zfr-3900000000-a8d3a8681d60e72703fa
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-176.5976043
predicted
DarkChem Lite v0.1.0
[M-H]-159.4243
predicted
DeepCCS 1.0 (2019)
[M+H]+176.4729043
predicted
DarkChem Lite v0.1.0
[M+H]+161.78232
predicted
DeepCCS 1.0 (2019)
[M+Na]+167.87546
predicted
DeepCCS 1.0 (2019)

Drug created at June 10, 2014 15:46 / Updated at June 12, 2020 16:52